| 1. | | Recruiting | ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
Conditions: Recurrent Melanoma; stage III melanoma; Stage IV Melanoma |
| 2. | | Recruiting | ABT-751 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That is Refractory to Taxane Therapy
Conditions: recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer |
| 3. | | Recruiting | ABX-EGF in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Chemotherapy
Conditions: adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent colon cancer; stage IV colon cancer; recurrent rectal cancer; ... |
| 4. | | Recruiting | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 5. | | Recruiting | Adjuvant Oxaliplatin and Capecitabine Compared With Fluorouracil and Leucovorin in Treating Chemotherapy-Naïve (Not Previously Treated) Patients Who Have Undergone Resection for Stage III Colon Cancer
Condition: stage III colon cancer |
| 6. | | Recruiting | AEE788 in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
Conditions: adult glioblastoma; recurrent adult brain tumor; adult giant cell glioblastoma; adult gliosarcoma |
| 7. | | Recruiting | AG-858 and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Were Previously Treated With Imatinib Mesylate
Conditions: chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia |
| 8. | | Recruiting | Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia |
| 9. | | Recruiting | Anti-Thymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplantation for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Graft Versus Host Disease; secondary acute myeloid leukemia |
| 10. | | Recruiting | APC8015 (Provenge®) in Treating Patients With Asymptomatic Metastatic Androgen-Independent Prostate Cancer
Conditions: adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer |
| 11. | | Recruiting | APC8015F in Treating Patients With Progressive Metastatic Prostate Cancer and Disease-Related Pain
Conditions: adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer |
| 12. | | Recruiting | Atrasentan in Treating Patients With Hormone-Naive Prostate Cancer
Conditions: recurrent prostate cancer; stage I prostate cancer; stage II prostate cancer; stage III prostate cancer; adenocarcinoma of the prostate |
| 13. | | Recruiting | BAY 43-9006 in Treating Patients With Imatinib Mesylate-Resistant Chronic Phase Chronic Myelogenous Leukemia
Conditions: chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia; relapsing chronic myelogenous leukemia |
| 14. | | Recruiting | Bendamustine in Treating Patients With Rituximab-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma
Conditions: adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma |
| 15. | | Recruiting | Bevacizumab and Trastuzumab (Herceptin®) in Treating Women With Relapsed or Metastatic Breast Cancer
Conditions: recurrent breast cancer; stage IIIC breast cancer; stage IV breast cancer; stage IIIB breast cancer |
| 16. | | Recruiting | Bevacizumab in Treating Patients With Metastatic Breast or Colorectal Cancer Who Received Bevacizumab on a Phase II or Phase III Clinical Trial
Conditions: stage IV breast cancer; recurrent breast cancer; stage IV colon cancer; Stage IV rectal cancer |
| 17. | | Recruiting | Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma |
| 18. | | Recruiting | BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate
Conditions: chronic phase chronic myelogenous leukemia; relapsing chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia |
| 19. | | Recruiting | BMS-599626 in Treating Patients With Metastatic Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 20. | | Recruiting | Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Conditions: recurrent adult Hodgkin's lymphoma; recurrent adult Burkitt's lymphoma; post-transplant lymphoproliferative disorder; ... |
| 21. | | Recruiting | Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Conditions: grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma; marginal zone lymphoma |
| 22. | | Recruiting | Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy
Condition: recurrent adult diffuse large cell lymphoma |
| 23. | | Recruiting | Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer |
| 24. | | Recruiting | Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
Conditions: Non-small cell lung cancer; stage I non-small cell lung cancer |
| 25. | | Recruiting | Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Conditions: localized unresectable adult primary liver cancer; recurrent adult primary liver cancer; adult primary hepatocellular carcinoma |
| 26. | | Recruiting | Continued Use of Monoclonal Antibody ABX-EGF in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)
Condition: Stage IV Renal Cell Cancer |
| 27. | | Recruiting | CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
Conditions: Recurrent Melanoma; stage III melanoma; Stage IV Melanoma |
| 28. | | Recruiting | CP-724,714 in Treating Patients With Metastatic Breast Cancer
Conditions: recurrent breast cancer; stage IV breast cancer; Male Breast Cancer |
| 29. | | Recruiting | CpG 7909 in Treating Patients With Cutaneous T-Cell Lymphoma
Conditions: Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndrome |
| 30. | | Recruiting | Darbepoetin alfa in Treating Anemic Patients With Myelodysplastic Syndromes
Conditions: Anemia; Fatigue; Myelodysplastic Syndromes |
| 31. | | Recruiting | Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Conditions: stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage II breast cancer |
| 32. | | Recruiting | Docetaxel and Carboplatin With or Without Zoledronate in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung; large cell lung cancer; Squamous Cell Lung Cancer; stage IIIB non-small cell lung cancer; ... |
| 33. | | Recruiting | Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
Conditions: adenocarcinoma of the prostate; recurrent prostate cancer |
| 34. | | Recruiting | Epoetin alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy
Conditions: adult solid tumor; Anemia; Leukemia; Lymphoma; plasma cell neoplasm |
| 35. | | Recruiting | Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Conditions: transitional cell carcinoma of the bladder; stage 0 bladder cancer; stage I bladder cancer |
| 36. | | Recruiting | FR901228 in Treating Patients With Metastatic Renal Cell Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer |
| 37. | | Recruiting | Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Condition: recurrent adult Hodgkin's lymphoma |
| 38. | | Recruiting | Gene Therapy Combined With Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer That Cannot Be Surgically Removed
Conditions: adenocarcinoma of the pancreas; stage III pancreatic cancer |
| 39. | | Recruiting | Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
Conditions: adult anaplastic oligodendroglioma; recurrent adult brain tumor; adult glioblastoma; adult anaplastic astrocytoma; adult giant cell glioblastoma; ... |
| 40. | | Recruiting | Green Tea Extract (Polyphenon® E) and Low-Dose Aspirin in Preventing Cancer in Women at High Risk For Developing Breast Cancer
Condition: Breast Cancer |
| 41. | | Recruiting | GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/neu
Conditions: stage IV breast cancer; Male Breast Cancer; recurrent breast cancer |
| 42. | | Recruiting | Interleukin-13 PE38QQR Immunotoxin Compared With Carmustine Implant in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
Conditions: adult glioblastoma; recurrent adult brain tumor; adult giant cell glioblastoma; adult gliosarcoma |
| 43. | | Recruiting | Letrozole in Preventing Breast Cancer in Postmenopausal Women
Conditions: Breast Cancer; breast cancer in situ |
| 44. | | Recruiting | LY317615 in Treating Patients With Relapsed or Refractory Lymphoma
Condition: recurrent adult diffuse large cell lymphoma |
| 45. | | Recruiting | LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 46. | | Recruiting | Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
Conditions: adult brain tumor; Fatigue; cognitive/functional effects |
| 47. | | Recruiting | Monoclonal Antibody ABX-EGF as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer |
| 48. | | Recruiting | Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
Conditions: Colorectal Cancer; Esophageal Cancer; kidney tumor; Lung Cancer; Pancreatic Cancer; Prostate Cancer |
| 49. | | Recruiting | Monoclonal Antibody Therapy in Treating Patients With Progressive Stage III or Stage IV Melanoma
Conditions: stage III melanoma; Stage IV Melanoma; Recurrent Melanoma |
| 50. | | Recruiting | Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Conditions: stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer |
